Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Fatigue in men with castration resistant prostate cancer treated with enzalutamide

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 21.10.16
Views: 1947

Dr Simon Chowdhury - Guy's Hospital, London, UK

Dr Chowdhury speaks with ecancertv at ESMO 2016 about the effects of enzalutamide, an androgen-receptor antagonist, on men with prostate cancer that has not responded to testosterone-lowering.

Focusing on the side effects of four trials, he describes how the low incidence of fatigue is a comparably minor risk, considering the overall benefits of enzalutamide therapy.

Dr Chowdhury also spoke with ecancer about cancer registries here.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation